EP3720871A4 - Immunotolérance ciblée - Google Patents

Immunotolérance ciblée Download PDF

Info

Publication number: EP3720871A4
Authority: EP; European Patent Office
Prior art keywords: immuntolerance; targeted; targeted immuntolerance
Prior art date: 2017-12-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP18887096.8A

Other languages

German (de)

English (en)

Other versions

EP3720871A1 (fr

Inventor

Nathan HIGGINSON-SCOTT

Joanne L. Viney

Jyothsna Visweswaraiah

Erik Robert Sampson

Kevin Lewis Otipoby

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pandion Operations Inc

Original Assignee

Pandion Operations Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-12-06

Filing date

2018-11-28

Publication date

2021-09-15

2018-05-24 Priority claimed from US15/988,311 external-priority patent/US10676516B2/en

2018-08-23 Priority claimed from US16/109,875 external-priority patent/US10174091B1/en

2018-11-28 Application filed by Pandion Operations Inc filed Critical Pandion Operations Inc

2020-10-14 Publication of EP3720871A1 publication Critical patent/EP3720871A1/fr

2021-09-15 Publication of EP3720871A4 publication Critical patent/EP3720871A4/fr

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Toxicology (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

EP18887096.8A 2017-12-06 2018-11-28 Immunotolérance ciblée Withdrawn EP3720871A4 (fr)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US201762595357P	2017-12-06	2017-12-06
US201762595348P	2017-12-06	2017-12-06
US201862675972P	2018-05-24	2018-05-24
US15/988,311 US10676516B2 (en)	2017-05-24	2018-05-24	Targeted immunotolerance
PCT/US2018/034334 WO2018217989A1 (fr)	2017-05-24	2018-05-24	Immunotolérance ciblée
US201862721644P	2018-08-23	2018-08-23
US16/109,875 US10174091B1 (en)	2017-12-06	2018-08-23	IL-2 muteins
US16/109,897 US10174092B1 (en)	2017-12-06	2018-08-23	IL-2 muteins
PCT/US2018/062780 WO2019112852A1 (fr)	2017-12-06	2018-11-28	Immunotolérance ciblée

Publications (2)

Publication Number	Publication Date
EP3720871A1 EP3720871A1 (fr)	2020-10-14
EP3720871A4 true EP3720871A4 (fr)	2021-09-15

Family

ID=66751175

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP18887096.8A Withdrawn EP3720871A4 (fr)	2017-12-06	2018-11-28	Immunotolérance ciblée

Country Status (3)

Country	Link
EP (1)	EP3720871A4 (fr)
JP (1)	JP2021505156A (fr)
WO (1)	WO2019112852A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP7165717B2 (ja)	2017-03-15	2022-11-04	パンディオン・オペレーションズ・インコーポレイテッド	標的免疫寛容
MX2019013517A (es)	2017-05-24	2020-08-17	Pandion Operations Inc	Inmunotolerancia dirigida.
US10946068B2 (en)	2017-12-06	2021-03-16	Pandion Operations, Inc.	IL-2 muteins and uses thereof
US10174091B1 (en)	2017-12-06	2019-01-08	Pandion Therapeutics, Inc.	IL-2 muteins
USRE50550E1 (en)	2017-12-06	2025-08-26	Pandion Operations, Inc.	IL-2 muteins and uses thereof
CA3083941A1 (fr) *	2017-12-06	2019-06-13	Pandion Therapeutics, Inc.	Muteines d'il-2 et leurs utilisations
EP3972992A4 (fr)	2019-05-20	2023-07-19	Pandion Operations, Inc.	Immunotolérance ciblée madcam
PH12022550165A1 (en)	2019-07-26	2023-05-08	Visterra Inc	Interleukin-2 agents and uses thereof
US20210188934A1 (en)	2019-12-20	2021-06-24	Regeneron Pharmaceuticals, Inc.	Novel il2 agonists and methods of use thereof
WO2021140416A2 (fr)	2020-01-10	2021-07-15	Bright Peak Therapeutics Ag	Polypeptides il-2 modifiés et leurs utilisations
WO2021168079A1 (fr)	2020-02-21	2021-08-26	Pandion Operations, Inc.	Immunotolérance ciblée sur un tissu avec un effecteur cd39
EP4255466A1 (fr)	2020-12-04	2023-10-11	Visterra, Inc.	Procédés d'utilisation d'agents d'interleukine-2
CA3222357A1 (fr)	2021-07-09	2023-01-12	Bertolt Kreft	Polypeptides il-2 modifies pour le traitement de maladies inflammatoires et auto-immunes

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015164815A1 (fr) *	2014-04-24	2015-10-29	The Board Of Trustees Of The Leland Stanford Junior University	Superagonistes, agonistes et antagonistes partiels de l'interleukine-2
WO2016164937A2 (fr) *	2015-04-10	2016-10-13	Amgen Inc.	Mutéines de l'interleukine-2 pour l'expansion de lymphocytes t régulateurs
WO2018217989A1 (fr) *	2017-05-24	2018-11-29	Pandion Therapeutics, Inc.	Immunotolérance ciblée
WO2019112854A1 (fr) *	2017-12-06	2019-06-13	Pandion Therapeutics, Inc.	Mutéines d'il-2 et leurs utilisations
WO2020061142A1 (fr) *	2018-09-18	2020-03-26	Pandion Therapeutics, Inc.	Immunotolérance ciblée

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020041865A1 (en) *	2000-01-20	2002-04-11	Richard Austin	Methods for treating tumors
US7611700B2 (en) *	2002-09-09	2009-11-03	Hanall Pharmaceuticals, Co., Ltd.	Protease resistant modified interferon alpha polypeptides
CN1956738B (zh) *	2004-01-09	2013-05-29	辉瑞大药厂	MAdCAM抗体
AU2005227263A1 (en) *	2004-03-05	2005-10-06	Novartis Vaccines And Diagnostics, Inc.	In vitro test system for predicting patient tolerability of therapeutic agents
US9546203B2 (en) *	2013-03-14	2017-01-17	Amgen Inc.	Aglycosylated Fc-containing polypeptides with cysteine substitutions
US10174091B1 (en) *	2017-12-06	2019-01-08	Pandion Therapeutics, Inc.	IL-2 muteins

2018
- 2018-11-28 WO PCT/US2018/062780 patent/WO2019112852A1/fr not_active Ceased
- 2018-11-28 EP EP18887096.8A patent/EP3720871A4/fr not_active Withdrawn
- 2018-11-28 JP JP2020531046A patent/JP2021505156A/ja not_active Abandoned

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015164815A1 (fr) *	2014-04-24	2015-10-29	The Board Of Trustees Of The Leland Stanford Junior University	Superagonistes, agonistes et antagonistes partiels de l'interleukine-2
WO2016164937A2 (fr) *	2015-04-10	2016-10-13	Amgen Inc.	Mutéines de l'interleukine-2 pour l'expansion de lymphocytes t régulateurs
WO2018217989A1 (fr) *	2017-05-24	2018-11-29	Pandion Therapeutics, Inc.	Immunotolérance ciblée
WO2019112854A1 (fr) *	2017-12-06	2019-06-13	Pandion Therapeutics, Inc.	Mutéines d'il-2 et leurs utilisations
WO2020061142A1 (fr) *	2018-09-18	2020-03-26	Pandion Therapeutics, Inc.	Immunotolérance ciblée

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2019112852A1 *
TOBIAS JAHN ET AL: "An Il12-Il2-Antibody Fusion Protein Targeting Hodgkin's Lymphoma Cells Potentiates Activation Of Nk And T Cells For An Anti-Tumor Attack", PLOS ONE, vol. 7, no. 9, 18 September 2012 (2012-09-18), pages e44482, XP055588597, DOI: 10.1371/journal.pone.0044482 *

Also Published As

Publication number	Publication date
JP2021505156A (ja)	2021-02-18
WO2019112852A1 (fr)	2019-06-13
EP3720871A1 (fr)	2020-10-14

Publication	Publication Date	Title
DK3731771T3 (da)	2023-08-28	V462033dk00
EP3596108A4 (fr)	2020-12-23	Immunotolérance ciblée
EP3720871A4 (fr)	2021-09-15	Immunotolérance ciblée
CL2018000524S1 (es)	2018-10-05	Golilla
DE202018003363U8 (de)	2019-01-24	Handgelenkssphygmomanometer
EP3634404C0 (fr)	2024-11-20	Inhibiteurs de magl à base de pyrazole
EP3589248A4 (fr)	2021-01-06	Cryothérapies
EP3588580A4 (fr)	2020-12-02	Diode schottky mos à tranchée
DK3351526T3 (da)	2021-02-08	Diisopentylterephthalat
EP3876986A4 (fr)	2022-06-01	Immunotolérance ciblée
EP3697802A4 (fr)	2021-11-24	Analogues de saponine triterpénique
EP3634397A4 (fr)	2021-03-17	Chromophores ir à base de polyméthine hétérocyclyle
DK3568655T3 (da)	2023-04-17	Rekuperator
DK3571580T5 (da)	2021-11-08	Load-logical-and-shift-guarded-instruktion
EP3654852A4 (fr)	2020-06-17	Garrot
DK3612237T3 (da)	2021-12-06	Genterapi
EP3575467A4 (fr)	2020-03-18	Tissu non tissé filé-lié
EP3611402A4 (fr)	2020-04-15	Servocylindre
EP3714787A4 (fr)	2021-03-17	Biocapteur
DK3576686T3 (da)	2022-01-03	Brokbind
DK3568506T3 (da)	2021-03-01	Offeranode
EP3689701A4 (fr)	2021-06-16	Boggie
EP3569893A4 (fr)	2020-01-08	Tendeur de chaîne
EP3687383C0 (fr)	2024-10-16	Electrogustometre
DK3510051T3 (da)	2020-03-16	Carboxylalkylchitosan

Legal Events

Date	Code	Title	Description
2019-06-15	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2020-09-11	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2020-09-11	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2020-10-14	17P	Request for examination filed	Effective date: 20200605
2020-10-14	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2020-10-14	AX	Request for extension of the european patent	Extension state: BA ME
2020-11-18	RIN1	Information on inventor provided before grant (corrected)	Inventor name: VISWESWARAIAH, JYOTHSNA Inventor name: VINEY, JOANNE L. Inventor name: SAMPSON, ERIK ROBERT Inventor name: HIGGINSON-SCOTT, NATHAN Inventor name: OTIPOBY, KEVIN LEWIS
2020-12-02	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: PANDION OPERATIONS, INC.
2021-03-17	DAV	Request for validation of the european patent (deleted)
2021-03-17	DAX	Request for extension of the european patent (deleted)
2021-09-15	A4	Supplementary search report drawn up and despatched	Effective date: 20210813
2021-09-15	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 38/00 20060101ALI20210809BHEP Ipc: C07K 19/00 20060101ALI20210809BHEP Ipc: C07K 14/55 20060101AFI20210809BHEP
2025-05-23	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN
2025-06-25	18W	Application withdrawn	Effective date: 20250521